SILENCE THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8 USD | 0.00% |
|
0.00% | +433.33% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 446.8 | 528.5 | 452.6 | 527.7 | 808.6 | - | - |
| Enterprise Value (EV) 2 | 409.3 | 454.9 | 452.6 | 473.9 | 717.3 | 725.6 | 776.8 |
| P/E ratio | -13.4 x | -13.7 x | -9.99 x | -11.6 x | -46.2 x | -33.2 x | -26.2 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 81.5 x | 42.6 x | 25.9 x | 20.8 x | 36.5 x | 22.2 x | 30 x |
| EV / Revenue | 74.7 x | 36.6 x | 25.9 x | 18.7 x | 32.4 x | 20 x | 28.9 x |
| EV / EBITDA | -11.6 x | -10 x | -9.41 x | - | -11.8 x | -101 x | -10.6 x |
| EV / FCF | -36.3 x | 420 x | -9.93 x | - | -17 x | -8.38 x | -7.65 x |
| FCF Yield | -2.76% | 0.24% | -10.1% | - | -5.9% | -11.9% | -13.1% |
| Price to Book | - | - | - | - | 35 x | 35.4 x | 425 x |
| Nbr of stocks (in thousands) | 27,769 | 29,928 | 35,893 | 38,670 | 46,615 | - | - |
| Reference price 3 | 22.00 | 23.89 | 15.25 | 17.37 | 21.60 | 21.60 | 21.60 |
| Announcement Date | 3/30/21 | 3/17/22 | 3/15/23 | 3/13/24 | - | - | - |
1USD in Million2GBP in Million3USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.244 | 5.479 | 12.42 | 17.5 | 25.38 | 22.15 | 36.37 | 26.92 |
| EBITDA 1 | -22.25 | -35.35 | -45.39 | -48.11 | - | -60.54 | -7.206 | -73.08 |
| EBIT 1 | -22.73 | -35.85 | -45.81 | -48.59 | -49.6 | -53.02 | -55.36 | -87.05 |
| Operating Margin | -9,317.21% | -654.26% | -369.02% | -277.66% | -195.48% | -239.35% | -152.23% | -323.33% |
| Earnings before Tax (EBT) 1 | -22.87 | -36.04 | -45.86 | -47.37 | -50.31 | -50.19 | -75.89 | -113.6 |
| Net income 1 | -19.58 | -32.55 | -39.41 | -40.49 | -43.27 | -42.72 | -72.69 | -107.2 |
| Net margin | -8,025.41% | -594.03% | -317.44% | -231.35% | -170.51% | -192.84% | -199.9% | -398.17% |
| EPS 2 | - | -1.638 | -1.742 | -1.527 | -1.491 | -0.4675 | -0.6507 | -0.8253 |
| Free Cash Flow 1 | - | -11.29 | 1.084 | -45.6 | - | -42.3 | -86.6 | -101.6 |
| FCF margin | - | -206% | 8.73% | -260.53% | - | -190.96% | -238.13% | -377.37% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 4/14/20 | 3/30/21 | 3/17/22 | 3/15/23 | 3/13/24 | - | - | - |
1GBP in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.146 | 4.333 | 5.845 | 3.156 | 3.414 | 6.57 | 5.722 | 3.643 | 9.365 | 3.371 | 4.765 | 8.136 | 11.37 | 9.104 | 2.798 | 2.099 | 3.55 | 13.05 | 3.5 | 3.5 | 1.9 |
| EBITDA | -13.98 | - | -22.02 | - | - | - | -9.21 | -13.98 | - | -13.51 | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -14.19 | -21.65 | -22.27 | -12.28 | -11.26 | -23.55 | -9.922 | -14.09 | -24.01 | -13.62 | -10.96 | -24.58 | -12.15 | -11.46 | -12.7 | -13.3 | -12.5 | -5.6 | -14.7 | -15.8 | - |
| Operating Margin | -1,238.48% | -499.75% | -380.98% | -389.23% | -329.91% | -358.39% | -173.4% | -386.74% | -256.39% | -404.06% | -230.03% | -302.14% | -106.81% | -125.85% | -453.86% | -633.59% | -352.11% | -42.91% | -420% | -451.43% | - |
| Earnings before Tax (EBT) 1 | -13.33 | -22.71 | -22.58 | -12.05 | -11.23 | -23.28 | -9.572 | -13.42 | -22.99 | -9.326 | -15.05 | -24.38 | -12.67 | -12.01 | -10.66 | -14.97 | -12.5 | -5.6 | -14.7 | -15.8 | - |
| Net income 1 | -11.03 | -21.52 | -20.05 | -9.929 | -9.434 | -19.36 | -7.684 | -11.94 | -19.62 | -7.103 | -20.64 | -27.74 | -10.2 | -10.4 | -8.25 | -14.41 | -2.9 | -4 | -13.1 | -14.2 | - |
| Net margin | -962.39% | -496.61% | -342.99% | -314.61% | -276.33% | -294.7% | -134.29% | -327.72% | -209.54% | -210.71% | -433.2% | -341.02% | -89.71% | -114.25% | -294.85% | -686.61% | -81.69% | -30.65% | -374.29% | -405.71% | - |
| EPS 2 | - | -1.070 | -0.9462 | - | - | -0.8452 | - | -0.4873 | -0.8024 | - | -0.4775 | -0.7290 | -0.3559 | -0.3668 | -0.2722 | -0.4792 | -0.0774 | -0.0570 | -0.1239 | -0.1290 | -0.1410 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/14/20 | 3/30/21 | 8/12/21 | 11/16/21 | 3/17/22 | 3/17/22 | 5/16/22 | 8/11/22 | 8/11/22 | 11/10/22 | 3/15/23 | 3/15/23 | 5/16/23 | 8/16/23 | 11/14/23 | 3/13/24 | - | - | - | - | - |
1GBP in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 13.5 | 37.4 | 73.5 | - | 53.8 | 91.3 | 82.9 | 31.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -11.3 | 1.08 | -45.6 | - | -42.3 | -86.6 | -102 |
| ROE (net income / shareholders' equity) | - | -359% | -448% | - | - | -151% | -9.59% | -199% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | - | 0.6200 | 0.6100 | 0.0500 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.01 | 0.51 | 1.31 | 0.14 | - | 2 | 10 | 20 |
| Capex / Sales | 3.69% | 9.33% | 10.56% | 0.8% | - | 9.03% | 27.5% | 74.29% |
| Announcement Date | 4/14/20 | 3/30/21 | 3/17/22 | 3/15/23 | 3/13/24 | - | - | - |
1GBP in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
21.6
USD
Average target price
55.8
USD
Spread / Average Target
+158.27%
EPS Revisions
- Stock Market
- Equities
- SLN Stock
- SLNCF Stock
- Financials Silence Therapeutics plc
